SCHEMBL19670545

SCHEMBL19670545

CCN1CCCN(C(=O)Nc2ccccn2)c2nc(N3CCC(C(F)(F)F)C3)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 1/20 0.40
▸ TRPV1 Q8NER1 1/20 0.39
▸ TRPV3 Q8NET8 2/20 0.37
▸ DGAT2 Q96PD7 1/20 0.36
▸ MAP3K12 Q12852 1/20 0.36
▸ MAP4K4 O95819 1/20 0.35
▸ PDE10A Q9Y233 1/20 0.35
▸ FAAH O00519 1/20 0.35
▸ MTOR P42345 2/20 0.34
▸ PIK3R1 P27986 1/20 0.34
▸ CHRNA7 P36544 1/20 0.34
▸ CHRNA10 Q9GZZ6 1/20 0.34
▸ CHRNA9 Q9UGM1 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ JAK3 P52333 1/20 0.34
▸ BTK Q06187 1/20 0.34
▸ SCN10A Q9Y5Y9 1/20 0.33
▸ TRPM8 Q7Z2W7 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19706295 1.00 FGFR4 (0.40) FGFR4TRPV1TRPV3DGAT2MAP3K12
SCHEMBL19706102 0.96 FGFR4 (0.40) FGFR4TRPV1TRPV3DGAT2MAP4K4
SCHEMBL19706272 0.88 TRPV3 (0.40) FGFR4TRPV3MAP4K4SCN10A
SCHEMBL19670324 0.87 MAP4K4 (0.39) TRPV3MAP4K4FAAHSCN10A
SCHEMBL19706161 0.87 TRPV3 (0.38) TRPV3MAP4K4MTORNPC1SCN10A
SCHEMBL19670523 0.87 TRPV3 (0.38) TRPV3MAP4K4MTORNPC1SCN10A
SCHEMBL19670596 0.85 FGFR4 (0.40) FGFR4TRPV1NPC1SCN10ATRPM8
SCHEMBL19670627 0.85 FGFR4 (0.40) FGFR4TRPV1NPC1SCN10ATRPM8
SCHEMBL19706163 0.85 FGFR4 (0.40) FGFR4TRPV1NPC1SCN10ATRPM8
SCHEMBL19706197 0.85 DEGS1 (0.39) FGFR4TRPV3MAP4K4SCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2020-03-17 — — US disclosed
US-20190048016-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2019-02-14 — — US disclosed
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2017-12-14 — — US disclosed
US-9834558-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-12-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 FGFR4 1754/4885TRPV1 3670/4885TRPV3 4093/4885
US-20190048016-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 FGFR4 1926/4885TRPV1 3814/4885TRPV3 4136/4885
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators SIRT1, SIRT3, SIRT2 FGFR4 1754/4885TRPV1 3670/4885TRPV3 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback